CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Phase 2 Recruiting
27 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
50 enrolled
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
43 enrolled
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 Recruiting
20 enrolled
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Phase 3 Recruiting
421 enrolled
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2 Recruiting
40 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Recruiting
100 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
15 enrolled
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 Recruiting
12 enrolled
BRAZAN
Phase 2 Recruiting
60 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Recruiting
200 enrolled
GLOASIS
Phase 2 Recruiting
100 enrolled
CONFIRM
Phase NA Recruiting
70 enrolled
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Phase 2 Recruiting
60 enrolled
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
Phase 1/2 Recruiting
27 enrolled
Avo In R/R And Previously Untreated MCL
Phase 1/2 Recruiting
72 enrolled
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Phase 1 Recruiting
20 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
FIL_COLUMN
Phase 2 Recruiting
49 enrolled
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Phase 1 Recruiting
68 enrolled
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
80 enrolled
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
IMCL-2023
Phase 2 Recruiting
50 enrolled
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 Recruiting
24 enrolled
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2 Recruiting
25 enrolled
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Phase 2 Recruiting
27 enrolled
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Phase NA Recruiting
34 enrolled
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
36 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Recruiting
500 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
30 enrolled
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Phase 2 Recruiting
40 enrolled
ZANU-TAFA
Phase 1/2 Recruiting
27 enrolled
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Phase 2 Recruiting
45 enrolled
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
Phase NA Recruiting
50 enrolled
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Recruiting
45 enrolled
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Phase 1 Recruiting
15 enrolled
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 Recruiting
148 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Phase 1/2 Recruiting
84 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled